COA Semaglutide (GLP-1 Analogue) Certificate

Semaglutide (GLP-1 Analogue) — Clinically Proven Medication for Type 2 Diabetes & Weight Management

Semaglutide is a next-generation GLP-1 receptor agonist (glucagon-like peptide-1 analogue) indicated for the treatment of type 2 diabetes mellitus and chronic weight management in adults. Administered as a once-weekly subcutaneous injection or as a daily oral tablet, semaglutide delivers superior glycaemic control, meaningful weight reduction, and proven cardiovascular protection — making it one of the most prescribed and trusted medications in modern endocrinology.

What Is Semaglutide? Understanding the GLP-1 Analogue Mechanism

Semaglutide is a synthetic analogue of the endogenous incretin hormone GLP-1, structurally modified with a C-18 fatty acid chain to extend its half-life to approximately 7 days. This modification allows for convenient once-weekly dosing while maintaining sustained pharmacological activity.

How semaglutide works in the body:

• Stimulates glucose-dependent insulin secretion from pancreatic beta cells, reducing the risk of hypoglycaemia.
• Suppresses inappropriate glucagon release, preventing excess hepatic glucose output.
• Slows gastric emptying, leading to lower post-meal blood glucose spikes.
• Acts on hypothalamic appetite centres to promote satiety and reduce caloric intake.
• Supports beta-cell preservation and function over time.

Approved Indications: What Is Semaglutide Used For?

Semaglutide is approved by the FDA and EMA for:

• Type 2 Diabetes Mellitus (T2DM): to improve glycaemic control as an adjunct to diet and exercise.
• Chronic Weight Management (Obesity / Overweight): in adults with a BMI ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related comorbidity.
• Cardiovascular Risk Reduction: to lower the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease.

Key Clinical Benefits of Semaglutide GLP-1 Therapy

Clinical trials including the SUSTAIN and STEP programmes have confirmed semaglutide’s broad therapeutic profile:

Superior Blood Sugar Control

Semaglutide consistently reduces HbA1c by up to 1.8% from baseline — one of the most significant reductions among GLP-1 receptor agonists available. Patients experience fewer blood glucose fluctuations throughout the day, supporting long-term diabetes management and reducing the risk of diabetic complications.

Clinically Significant Weight Loss

In the landmark STEP 1 trial, participants receiving semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks — far exceeding placebo. For individuals with obesity or weight-related conditions, semaglutide represents a transformative option when combined with lifestyle intervention.

Cardiovascular Protection

The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo. This benefit positions semaglutide as a preferred agent for patients with T2DM at high cardiovascular risk.

Semaglutide Dosage, Forms & Administration Guide

Injectable Semaglutide (Subcutaneous)

• Starting dose: 0.25 mg subcutaneously once weekly for 4 weeks.
• Maintenance dose: Escalated to 0.5 mg, then 1 mg, and up to 2 mg weekly depending on clinical response and tolerability.
• Administered in the abdomen, thigh, or upper arm.
• Does not require refrigeration after first use (check product-specific storage instructions).

Oral Semaglutide (Tablet)

• Starting dose: 3 mg once daily for 30 days.
• Escalated to 7 mg, then 14 mg once daily as required.
• Must be taken on an empty stomach with no more than 120 ml of plain water, at least 30 minutes before the first food or drink of the day.
• Do not split, crush, or chew the tablet.

Semaglutide Side Effects: What to Expect

Semaglutide is generally well-tolerated. The majority of side effects are mild-to-moderate and gastrointestinal in nature, occurring most often during dose escalation:

Common Side Effects (≥ 5% of patients)

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal pain or discomfort
• Decreased appetite

These symptoms typically resolve within the first few weeks as the body adjusts to therapy. Slow dose titration helps minimise discomfort.

Important Safety Warnings

• Pancreatitis: Discontinue if acute pancreatitis is suspected.
• Thyroid C-cell tumours: Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
• Diabetic Retinopathy: Rapid improvements in glycaemic control may worsen diabetic retinopathy in predisposed patients.
• Renal Impairment: Monitor renal function during therapy initiation.

Who Is Semaglutide Right For? Patient Eligibility

Ideal Candidates for Semaglutide Therapy

• Adults with type 2 diabetes not adequately controlled on metformin or other oral agents.
• Individuals with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with comorbidities such as hypertension or dyslipidaemia.
• Patients with established cardiovascular disease seeking additional risk reduction.
• Those seeking a once-weekly injection for convenience and adherence.

Contraindications: When Semaglutide Should Not Be Used

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Type 1 diabetes mellitus or diabetic ketoacidosis.
• Known hypersensitivity to semaglutide or any excipient.
• Pregnancy or planned pregnancy (discontinue at least 2 months before conception).

Why Choose Semaglutide Over Other GLP-1 Analogues?

When compared to other GLP-1 receptor agonists such as liraglutide, dulaglutide, or exenatide, semaglutide consistently demonstrates:

• Greater HbA1c reductions across head-to-head clinical trials.
• Superior weight loss outcomes, particularly at the 2.4 mg weekly dose.
• Once-weekly subcutaneous dosing for maximum patient convenience.
• Strong cardiovascular outcomes data with MACE reduction.
• Availability in both injectable and oral formulations — the world’s first oral GLP-1 agonist.

Storage, Handling & Shelf Life of Semaglutide

Injectable Pen Storage

• Unopened pens: Store in a refrigerator at 2°C–8°C.
• Once in use: Store at room temperature (below 30°C) for up to 6 weeks.
• Keep away from heat, sunlight, and freezing temperatures.
• Do not use if the solution appears cloudy, discoloured, or contains particles.

Oral Tablet Storage

• Store below 30°C in the original blister packaging.
• Keep out of reach of children.
• Do not use past the stated expiry date.